Part A of the P-III (CheckMate -914) trial evaluating Opdivo + Yervoy in patients with localized RCC who have undergone full or partial removal of the kidney & are at mod. or high risk of relapse
The trial failed to meet its 1EPs of DFS as assessed by BICR & the safety profile was consistent with prior reported studies of the Opdivo + Yervoy in solid tumors. The therapy demonstrated clinical benefits across multiple RCC patient populations incl. Opdivo + Yervoy for untreated, intermediate & poor-risk RCC & for advanced RCC while Opdivo for 2L treatment of advanced or metastatic RCC
Opdivo or Opdivo + Yervoy is also being studied in combination with novel agents targeting alternative immunomodulatory molecules & pathways for RCC
Ref: Bussinesswire | Image: BMS
